Nuvation Bio Inc (NUVB)
2.62
-0.04
(-1.50%)
USD |
NYSE |
Apr 25, 16:00
2.625
0.00 (0.00%)
Pre-Market: 20:00
Nuvation Bio Cash from Financing (TTM): 0.628M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.628M |
September 30, 2023 | 0.915M |
June 30, 2023 | 1.096M |
March 31, 2023 | -2.639M |
December 31, 2022 | 1.327M |
September 30, 2022 | 1.458M |
June 30, 2022 | 1.168M |
Date | Value |
---|---|
March 31, 2022 | 4.827M |
December 31, 2021 | 625.53M |
September 30, 2021 | 757.62M |
June 30, 2021 | 758.16M |
March 31, 2021 | 758.10M |
December 31, 2020 | 133.14M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.639M
Minimum
Mar 2023
758.16M
Maximum
Jun 2021
233.95M
Average
1.458M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
iBio Inc | 10.68M |
Flora Growth Corp | 3.15M |
Lixte Biotechnology Holdings Inc | 3.143M |
Replimune Group Inc | 16.34M |
ABVC BioPharma Inc | 3.919M |